Montmorillonite as an Anti-Tuberculosis Rifampicin Drug Carrier: DFT and Experimental Study

被引:0
|
作者
Eva Scholtzová
Luboš Jankovič
Daniel Tunega
机构
[1] Slovak Academy of Sciences,Institute of Inorganic Chemistry
[2] University of Natural Resources and Life Sciences Vienna,Institute for Soil Research, Department of Forest and Soil Sciences
来源
Clays and Clay Minerals | 2023年 / 71卷
关键词
DFT-D3; Drug carrier; Hydrogen bonds; Molecular dynamics; Montmorillonite; Rifampicin;
D O I
暂无
中图分类号
学科分类号
摘要
A hybrid of montmorillonite (Mnt) and rifampicin (RIF) was synthesized and the structure and stability of the drug carrier system clarified. Density functional theory calculations involving dispersion corrections (DFT-D3) were performed to characterize interactions acting in the interlayer space of montmorillonite intercalated with rifampicin. The structure and stability of the RIF-Mnt intercalated complex were determined. Calculations revealed the deformation of the molecular structure of rifampicin after intercalation into the Mnt interlayer space due to the clay environment. The ansa chain of RIF was bent in the interlayer space compared with the structure of the RIF molecule in the monocrystal. RIF was keyed into the Mnt surface by means of numerous hydrogen bonds of weak to moderate strength. The calculated vibrational spectrum from ab initio molecular dynamics (AIMD) was in good agreement with the FTIR measured spectra and helped to analyze the overlapped vibrational bands. Based on analysis of structural stability, theoretical calculations revealed that Mnt is a suitable drug carrier for delayed release of the RIF drug. Batch adsorption experiments showed the large adsorption capacity of montmorillonite for RIF.
引用
收藏
页码:229 / 241
页数:12
相关论文
共 50 条
  • [41] EFFECTS ON THE LIVER OF ANTI-TUBERCULOSIS REGIMENS CONTAINING ISONIAZID AND RIFAMPICIN - LIGHT AND ELECTRON-MICROSCOPY STUDY
    PILHEU, JA
    DESALVO, MC
    KOCH, OR
    CHEST, 1979, 76 (03) : 363 - 363
  • [42] Tuberculosis Clinical Trial Update and the Current Anti-Tuberculosis Drug Portfolio
    Palomino, Juan Carlos
    Martin, Anandi
    CURRENT MEDICINAL CHEMISTRY, 2013, 20 (30) : 3785 - 3796
  • [43] First novel anti-tuberculosis drug in 40 years
    Randy Osborne
    Nature Biotechnology, 2013, 31 : 89 - 90
  • [44] Anti-tuberculosis drug resistance in patients with HIV and tuberculosis in South India
    Swaminathan, S
    Paramasivan, CN
    Ponnuraja, C
    Iliayas, S
    Rajasekaran, S
    Narayanan, RR
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2005, 9 (08) : 896 - 900
  • [45] Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus
    Kumar, A. K. Hemanth
    Chandrasekaran, V.
    Kannan, T.
    Murali, A. Lakshmi
    Lavanya, J.
    Sudha, V.
    Swaminathan, Soumya
    Ramachandran, Geetha
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (01) : 65 - 70
  • [46] Drug-Resistant Tuberculosis and Group 5 Anti-Tuberculosis Drugs
    Shokouhi, Shervin
    Darazam, Ilad Alavi
    ARCHIVES OF PEDIATRIC INFECTIOUS DISEASES, 2015, 3 (01):
  • [47] Cutaneous Leukocytoclastic Vasculitis Associated with Pulmonary Tuberculosis and an Anti-tuberculosis Drug
    Tanaka, Yuya
    Kobayashi, Takehiko
    Shimizu, Shigeki
    Kurahara, Yu
    INTERNAL MEDICINE, 2024, 63 (18) : 2587 - 2588
  • [48] Nationwide survey of anti-tuberculosis drug resistance in Mongolia
    Buyankhishig, B.
    Naranbat, N.
    Mitarai, S.
    Rieder, H. L.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2011, 15 (09) : 1201 - 1205
  • [49] An assessment survey of anti-tuberculosis drug management in Cambodia
    Uchiyama, Y
    Mao, TE
    Okada, K
    Chay, S
    Soum, MK
    Leng, C
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2006, 10 (02) : 153 - 159
  • [50] Anti-tuberculosis drug-induced liver injury
    Lim, Wei Shen
    Avery, Anthony
    Kon, Onn Min
    Dedicoat, Martin
    BMJ-BRITISH MEDICAL JOURNAL, 2023, 383